Phillip Koo:

There are questions about radium versus Pluvicto, and PEACE-3, and those patients could be eligible for Pluvicto, which they're correct, as long as it's PSMA positive. I sort of shiver a little, because I don't think it's… like, just because radium and Pluvicto are both radiopharmaceuticals doesn't mean they're interchangeable.

So, can you sort of help clarify that, and who might be better to undergo sort of that PEACE-3 regimen versus someone who might get Pluvicto in that pre-chemo setting.

Zachary Klaassen:

Yeah, great question, Phil. I think… I think… I'll spin off just a second, come back to that. There is some data that you can get both, and it is safe. We're not sure what the timing of that is between the two, but I think that's important as…

Radium's been around for, you know, nearly 20 years, and obviously lutetium or Pluvicto is somewhat newer. So we're feeling out that timing of sequencing therapies and what the safety net is for that. But going back to your question, generally, anybody with bone lesions, especially in that… in that… in that PEACE-3 core is a candidate for… for… for Radium-223. Now, whether that's… with visceral or not visceral. It's predominantly for bone lesions, so if you have 5 bone lesions and nothing else, I think you're a great candidate for radium. 

There's an important criteria for radioligand therapy. We talked earlier about PSMA-PET and the utilization of that. The patient has to have PSMA PET-positive lesions lighting up on that scan to be into that criteria of whether you could get lutetium or Pluvicto. So I think that's the easiest way to, sort of, that first delineation.

There may be some other nuances you need to discuss with your clinician, but I think that's one of the easier ones. It's more of a catch-all for radium, and it's a little more specific for radioligand therapy.